1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
Developmental and Epileptic Encephalopathies (DEE) - Epidemiology Forecast - 2032

Developmental and Epileptic Encephalopathies (DEE) - Epidemiology Forecast - 2032

  • May 2022
  • 172 pages
  • ID: 6276115
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

" Developmental and Epileptic Encephalopathy - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the DEE, historical and forecasted epidemiology as well as the DEE market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Geographies Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
Study Period: 2019-2032

Developmental and Epileptic Encephalopathy Disease Understanding and Treatment Algorithm
Developmental and Epileptic Encephalopathy (DEE) refers to a group of severe epilepsies that are characterized both by seizures, which are often drug-resistant, as well as encephalopathy, which is a term used to describe significant developmental delay or even loss of developmental skills. The syndromes of epileptic encephalopathies with onset in the neonatal period, infancy, and early childhood include early myoclonic encephalopathy, Ohtahara syndrome, West syndrome, Dravet syndrome (severe myoclonic epilepsy in infancy), Lennox–Gastaut syndrome (LGS), Landau–Kleffner syndrome (LKS), Epilepsy with continuous spike-and-waves during slow-wave sleep, Doose Syndrome (myoclonic atonic epilepsy), CDKL5 deficiency disorder (CDD), Tuberous sclerosis complex (TSC), SCN8A-DEE, and KCNQ2-DEE.

DEE Diagnosis
The diagnosis of these epileptic encephalopathies begins with an EEG which should include both the sleep and wake states. Moreover, Brain computed tomography (CT) scanning, and more specifically, magnetic resonance imaging (MRI) is also indicated. These should be performed before steroid treatment, which may lead to apparent atrophy on the CT or MRI scan.

Treatment
The approach to the treatment of epileptic encephalopathy has some of the general principles and approach to pediatric epilepsy treatment. The most appropriate anti-epileptic treatment is selected based on the type of epilepsy syndrome. Antiseizure medications includes clobazam, vigabatrin, zonisamide, phenobarbital, benzodiazapines, vigabatrin, and others are used for treatment of DEE. Steroids therapies, vagus nerve stimulation, ketogenic diet and epilepsy surgery are also used for management of DEE.

DEE Epidemiology
The DEE epidemiology division provides insights about historical and current DEE patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The’s report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by, diagnosed prevalent cases of DEE in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan market from 2019 to 2032.

Country Wise- DEE Epidemiology
This section provides glimpse of the DEE epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
• The total diagnosed prevalent cases of DEE in the 7MM were 302,897 in 2021, growing at a CAGR of 0.31% during the study period (2019–2032).
• Epidemiology assessed for the condition showed that the US, in 2021, accounted for approximately 129,437 diagnosed prevalent cases of DEE.
• Among the EU-5 countries in 2021, Germany had the highest diagnosed prevalent population of DEE with 21,041 cases, followed by France (17,258) and UK (16,381). In contrast, Spain had the lowest cases (11,743) in 2021.
• Japan accounted for 23,798 diagnosed prevalent DEE cases in 2021.
• LGS accounted for the highest number of diagnosed prevalent cases in 7MM. 79,396 cases, were observed in 2021 which are expected to increase by 2032.
• In EU5 countries, the diagnosed prevalent cases of Tuberous sclerosis complex were highest in Germany with 4,651 in 2021.

Scope of the Report
• The Developmental and Epileptic Encephalopathies (DEE) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Developmental and Epileptic Encephalopathies (DEE) Epidemiology Report and Model provide an overview of the global trends of Developmental and Epileptic Encephalopathies (DEE) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Developmental and Epileptic Encephalopathies (DEE) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Developmental and Epileptic Encephalopathies (DEE)

• The report provides the segmentation of the Developmental and Epileptic Encephalopathies (DEE) epidemiology

Report Highlights

• 11-year Forecast of Developmental and Epileptic Encephalopathies (DEE) epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Developmental and Epileptic Encephalopathies (DEE)
• Cases of Developmental and Epileptic Encephalopathies (DEE) by Mutation Types
• Developmental and Epileptic Encephalopathies (DEE) Cases associated with Clinical Manifestations
KOL views
We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Developmental and Epileptic Encephalopathies (DEE)?
• What are the key findings pertaining to the Developmental and Epileptic Encephalopathies (DEE) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Developmental and Epileptic Encephalopathies (DEE) across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Developmental and Epileptic Encephalopathies (DEE)?
• What are the currently available treatments of Developmental and Epileptic Encephalopathies (DEE)?

Reasons to buy
The Developmental and Epileptic Encephalopathies (DEE) Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Developmental and Epileptic Encephalopathies (DEE) market
• Quantify patient populations in the global Developmental and Epileptic Encephalopathies (DEE) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Developmental and Epileptic Encephalopathies (DEE) therapeutics in each of the markets covered

• Understand the magnitude of Developmental and Epileptic Encephalopathies (DEE) population by its epidemiology
• The Developmental and Epileptic Encephalopathies (DEE) Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

ref:plp2022

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on